Arati Suvas Desai MD
Hematologic Oncology, Neuro-Oncology
Assistant Professor, Medicine, Perelman School of Medicine
Join to View Full Profile
3400 Civic Center BlvdFl 23Philadelphia, PA 19104
Phone+1 215-615-5858
Dr. Desai is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Kentucky College of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2004 - Present
PA State Medical License 2009 - 2026
MD State Medical License 2006 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
Clinical Trials
- Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Start of enrollment: 2012 May 31
- Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2013 Oct 24
- Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Publications & Presentations
PubMed
- Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.Lauren Linkowski, Ian Messing, Melanie Berger, Casey Hollawell, Cole Friedes
International Journal of Radiation Oncology, Biology, Physics. 2026-07-02 - Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant ...Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, Ashley Teraishi, Catalina Raymond
AJNR. American Journal of Neuroradiology. 2026-05-29 - Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study.Hamed Akbari, Suyash Mohan, Fang Liu, Cecilia Jiang, Anahita Fathi Kazerooni
Nature Communications. 2026-05-13
Journal Articles
- Three‐Dimensional Echo Planar Spectroscopic Imaging for Differentiation of True Progression from Pseudoprogression in Patients with GlioblastomaArati Desai, Ronald L Wolf, MacLean Nasrallah, Suyash Mohan, Steven Brem, NMR in Biomedicine
Press Mentions
Losing Mom to Brain Cancer Fuels Penn Medicine Expert’s Mission for BreakthroughJuly 20th, 2022
STELLAR Trial Introduces New Treatment Options for Anaplastic AstrocytomaJanuary 31st, 2020
Glioblastoma Multiforme Translational Center of ExcellenceMarch 1st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
